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products have as strong a scientific 
basis as possible, giving governments 
and the public confidence in the 
findings and projections,” he said. The 
review is expected to report in August.
While the science now appears 
to be getting back on track, in a 
new article in the Proceedings of 
the National Academy of Science 
(published online) researchers believe 
lessons from the Montreal Protocol 
could speed up measures to deal with 
some of the pollutants that are potent 
greenhouse gases in the shorter 
term, while the massive reductions 
in carbon dioxide emissions are 
negotiated and implemented.
In spite of Copenhagen’s 
disappointments, Veerabhadran 
Ramanathan and Yangyang Xu, at the 
Scripps Institute of Oceanography in 
La Jolla, write that most participants 
agreed a ‘Copenhagen Accord’ which 
included that “deep cuts in global 
emissions are required according to 
science, and as documented by the 
IPCC Fourth Assessment Report with 
a view to reduce global emissions 
so as to hold the increase in global 
temperature below 2 degrees 
Celsius and take action to meet this 
objective.”
Ramanathan and Xu write that 
this 2ºC limit translates to a value of 
radiant energy that should not exceed 
an excess average of 2.5 watts per 
square metre of the Earth’s surface. 
But they state that the build-up of 
greenhouse gases is already adding 
3 watts per square metre. “Even if 
greenhouse gas emissions peak 
in 2015, the radiant energy will be 
exceeded,” they say.
They suggest that, while efforts are 
sought to stabilize the carbon dioxide 
concentration in the atmosphere by 
“massive decarbonisation” of the 
energy sector, other avenues might 
be pursued alongside. They argue 
that an effort to reduce short-lived 
greenhouse gases such as methane  
and hydrofluorocarbons could be a 
major target for action.
And they believe the “great success 
story” of the Montreal Protocol may 
provide a model. “Had CFC-11 and 
CFC-12 not been regulated, their 
greenhouse effects would have added 
0.6–1.6 watts per square metre of 
radiant energy by now and could have 
exceeded the carbon dioxide effect 
during this century,” they write.
“We just have to repeat this 
successful model.”Rarely have news editors have 
disagreed so profoundly over the 
significance of a scientific story than 
they did recently when The Lancet 
(2010, 375, 1525–1535) published a 
paper indicating that whole-genome 
sequencing can provide clinically 
important information on individual 
patients. The genome discussed in the 
paper from Stanford University School 
of Medicine belonged to one of the 
authors, Stephen Quake. Analysis 
of 2.6 million single nucleotide 
polymorphisms in his DNA, and 752 
copy number variations, showed that 
Quake had above-average genetic 
risks for myocardial infarction, type 2 
diabetes and certain cancers.
While some newspapers gave 
the breakthrough and its attendant 
health and ethical implications banner 
headlines, others ignored it altogether 
or reduced it to epigrammatic 
snippets. “A scientist has had all 
his DNA screened for diseases 
and susceptibility to treatments,” 
said The Daily Telegraph (30 April).  
“Prof Stephen Quake, at Stanford 
University, spent £33,000 having his 
genetic make-up mapped and then 
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Demand: Increasing individual genetic risk analysis may lead to growth in the market for pre-
ventative drugs. (Picture: Photolibrary.) 
For the first time in more than 30 
years, the outcome of Britain’s general 
election earlier this month failed to 
deliver an outright victory to one party 
and a liberal – conservative coalition 
has emerged. Europe is in the grip of 
debt troubles and voters may have 
been unsure of who may be best at 
handling the problem.
While eyes have been focused on 
Greece and the enormous bail-out 
loans agreed by other European states 
to help the country prevent defaulting 
on its debt, other commentators 
pointed out that the UK’s budget 
deficit is far larger than that of Greece.
On the eve of the election the 
European Commission predicted that 
the British deficit for this calendar 
year would be 12 per cent of GDP, the 
highest of all the 27 EU nations. The 
country’s budget shortfall was the 
third largest in the EU last year but is 
now set to overtake both Greece and 
Ireland. Greece’s painful measures, 
which have sparked so much protest, 
are estimated to reduce its deficit to 
9.3 per cent of GDP.
With such a serious budget shortfall 
facing the new British government, 
it is inevitable that science, higher 
education and health will face their 
share of wider cutbacks.
Indeed, The Times reported the 
governor of the Bank of England, 
Mervyn King, saying before the election 
that the austerity measures needed to 
tackle Britain’s budget deficit would 
be so unpopular that whoever won 
the election would not get back into 
government for a generation.
Science has generally fared 
quite well under the last Labour 
government, but the mood had 
begun to change in recent years as 
the budget problems loomed. The 
government’s pre- budget report in 
December last year announced that 
£600 million would be cut from higher 
education and science and research 
budgets by 2012–13.
The prospect of budget cuts 
prompted the House of Commons 
science and technology committee to 
launch an enquiry earlier this year to 
examine likely impacts. 
Science and health will not be immune 
from the deep spending cuts the 
new British government must now 
implement. Nigel Williams reports.
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analysed for different diseases and 
sensitivity to medication. The results, 
which revealed risks of heart disease, 
diabetes and prostate cancer, could 
pave the way to similar tests for the 
general public.”
The Daily Mirror on the same day 
was equally succinct, but at the same 
time both more and less informative: 
“A scientist has become the first 
person in the world to have his DNA 
screened. In a study published in 
The Lancet Prof Stephen Quake, a 
bioengineer at Stanford University, 
California, was examined for 55 
conditions, ranging from type 2 
diabetes to schizophrenia. But in 
another article heart scientist Prof 
Nilesh Samani, of Leicester University, 
wrote of ethical issues — ‘who should 
have their genome sequenced, what 
counselling be provided and who 
should have access to an individual’s 
genetic information’”.
At the other extreme, The 
Independent allocated an entire page 
to a report on the scientific work plus 
a background commentary by science 
editor Jeremy Laurance. An excellent 
graphic highlighted nine different 
conditions, the risk in each case faced 
by Quake and the average risk for men 
of his age in the general population.  
For example, his risks of developing 
obesity, heart disease, diabetes and 
depression were 63%, 58%, 55% and 
25%, respectively, as compared with 
average figures of 25%, 50%, 27% 
and 10%.
Both the news report and 
commentary referred to wider 
aspects of the development and 
wider application of genome analysis. 
Laurance explained how it can 
provide information to help individuals 
live with increased susceptibility to 
particular maladies (as Quake has 
done by beginning to take statins to 
prevent cardiovascular disease). The 
new technique will also help doctors 
to encourage patients predisposed 
to lung cancer to stop smoking, and 
those prone to obesity or diabetes to 
moderate their diets. 
In other cases, Laurance pointed 
out, the provision of genetic 
information could be positively 
harmful, the only outcome being that 
an affected individual would have to 
live under the shadow of a threatened 
disease. “Analysis of your genome 
could reveal you were carrying a gene 
for Huntingdon’s disease, a condition 
that kills people in their 20s and for 
which there is no treatment. Would 
there be benefit in that?” 
Dwarfed by a headline “The DNA 
death test”, the Daily Mail carried 
a similar chart (with most of the 
percentages different from those 
in The Independent, but with the 
same general relative risks). Medical 
correspondent Jenny Hope pointed 
out that we are rapidly approaching 
an era when everyone will be able to 
have their DNA scanned for evidence 
of disease propensities. She said that 
tests already available commercially 
at around £300 can read part of a 
person’s genome, and that others 
costing $2,000 (£1,300) give verdicts 
on the risks of 50 common diseases.
“Cardiologist Euen Ashley, one 
of the Stanford scientists, said the 
falling cost of genome sequencing 
would soon put screening of the 
full code within reach of the general 
public.” The $1,000 (£657) genome 
was coming fast. The challenge was 
in knowing what to do with all that 
information.
“Professor Henry Greely, from 
Stanford Law School, said patients, 
doctors and geneticists are about to 
be hit by a ‘tsunami’ of genetic data. 
‘We predict that an average person 
might need information about roughly 
100 genetic risks,’ he said. He warned 
that it would take at least five hours 
to counsel the average patient about 
their genetic risks of disease, in 
addition to many hours of analysis to 
assess the nature of the risks.”
The Guardian did most to 
explain the science behind the 
announcement. “The scientists began 
by building a data-base of gene 
variants and their links to medical 
conditions,” science correspondent 
Ian Sample wrote. “Atul Butte, who 
worked on the study, said: ‘We read 
thousands of publications and made a 
list of every single spot in the genome 
where we know that, for example, the 
letter A raises the risk of a particular 
disease, or the letter T confers 
protection.’” Although news editors 
had dramatically different feelings 
about the importance of this story, 
those who did cover it were united 
in one thing. None of them invoked 
those ethicists and commentators 
who can be relied upon to voice dire 
warnings about most advances in 
biomedicine. Good.
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